Format

Send to

Choose Destination
  • PMID: 28376213 was deleted because it is a duplicate of PMID: 27795228
J Natl Cancer Inst. 2016 Oct 30;109(2). pii: djw217. Print 2017 Feb.

Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.

Zhang Y1,2,3, Yang Y1,2,3, Zhang Z1,2,3, Fang W1,2,3, Kang S2,3,4, Luo Y5, Sheng J1,2,3, Zhan J1,2,3, Hong S1,2,3, Huang Y1,2,3, Zhou N1,2,3, Zhao H1,2,3, Zhang L1,2,3.

Author information

1
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
2
State Key Laboratory of Oncology in South China, Guangzhou, China.
3
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
4
Department of Anesthesiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
5
Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.

Abstract

Background:

Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown.

Methods:

Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases. Efficacy and toxicity were integrated by pairwise and network meta-analyses.

Results:

Thirty-six trials involving 18 889 patients using triple regimens (NK-1RA+serotonin receptor antagonists [5HT3RA] + dexamethasone) or duplex regimen (5HT3RA+dexamethasone) to control CINV were included in the analysis. Different NK-1RA-based triple regimens shared equivalent effect on CRs. In patients with HEC, almost all triple regimens showed statistically significantly higher CRs than duplex regimen (odds ratio [OR]duplex/triple = 0.47-0.66). However, in patients with MEC, only aprepitant-based triple regimen showed better effect than duplex regimen statistically significantly in CRs (ORduplex/triple = 0.52, 95% confidence interval [CI] = 0.34 to 0.68). No statistically significant difference of TRAEs was found among different triple regimens. Palonosetron-based triple regimens were equivalent to first-generation 5HT3RAs-based triple regimens for CRs. Moreover, different doses of dexamethasone plus NK-1RA and 5HT3RA showed no statistically significant difference in CRs.

Conclusions:

Different NK-1RAs-based triple regimens shared equivalent effect on CINV control. Various triple regimens had superior antiemetic effect than duplex regimen in patients with HEC. Only aprepitant-based triple regimen showed better CINV control compared with duplex regimen in patients receiving MEC. Palonosetron and first-generation 5HT3RAs might share equivalent CINV control in the combination of NK-1RAs and dexamethasone. Lower doses of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs.

PMID:
27795228
DOI:
10.1093/jnci/djw217
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center